The abstract is read at the publisher; the summary is JClub's.
Daraxonrasib, a first-in-class pan-RAS inhibitor, shrank tumors in more than 30% of previously treated RAS-mutant non-small cell lung cancer patients.
- Why it matters: Effective options are needed for advanced, previously treated RAS-mutant non-small cell lung cancer, where responses to targeted therapies remain limited.
- What they did: The study evaluated daraxonrasib activity in patients with RAS-mutant non-small cell lung cancer who had received prior treatment.
- The result: The observed tumor shrinkage supports continued development, including an ongoing phase III trial in lung cancer.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.